

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Kurman 1



	Section 1. Identifying Inform	ation						
	1. Given Name (First Name) Jonathan	2. Surname (Last Name) Kurman		3. Date 19-April-2020				
	4. Are you the corresponding author?	✓ Yes No						
	5. Manuscript Title Bronchoscopic Lung Volume Reduction: Who, What, Where, When?							
	6. Manuscript Identifying Number (if you know it)							
	Section 2. The Work Under Co	onsideration for Public	ation					
	Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interests	but not limited to grants, dat			c.) for			
	Section 3. Relevant financial a	activities outside the su	ubmitted work.					
	Place a check in the appropriate boxes ir of compensation) with entities as descrik clicking the "Add +" box. You should rep Are there any relevant conflicts of intered If yes, please fill out the appropriate info	bed in the instructions. Use ort relationships that were st?	e one line for each entity	y; add as many lines as you need				
	Name of Entity	Grant? Personal Non-	-Financial other?	Comments				
L	evel Ex			nsulting				
Ν	Medtronic		CO	nsulting				
P	Pinnacle Biologics		✓ ed	ucational courses				
В	liodesix		Spr	eaking				

Kurman 2



Section 4. Intellectual Property Patents & Copyrights						
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume						
Section 5. Relationships not covered above						
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?						
Yes, the following relationships/conditions/circumstances are present (explain below):						
No other relationships/conditions/circumstances that present a potential conflict of interest						
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.						
Section 6. Disclosure Statement						
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.						
Dr. Kurman reports personal fees from Level Ex, personal fees from Medtronic, other from Pinnacle Biologics, personal fees from Biodesix, outside the submitted work; .						

Evaluation and Feedback

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$

Kurman 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your



Section 1.	Identifying Inform	nation					
1. Given Name (Fire			me (Last Nar	ne)		3. Date 26-March-2020	
4. Are you the corresponding author? Yes Volume				•	Corresponding Author's Name Jon Kurman		
5. Manuscript Title Interventional Pu	lmonary and Advance	ed Broncho					
6. Manuscript Iden	tifying Number (if you k	now it)					
Section 2.	The Work Under C	: :onsidera	tion for P	ublication			
any aspect of the su statistical analysis, e Are there any rele	ıbmitted work (includin	g but not lin		its, data monitoring		ent, commercial, private foundation, eudy design, manuscript preparation,	tc.) for
Section 3.	Relevant financial	activities	s outside 1	the submitted	work.		
of compensation) clicking the "Add Are there any rele	with entities as descr	ribed in the eport relation rest?	e instruction inships that Yes	ns. Use one line fo	or each er	cial relationships (regardless of am ntity; add as many lines as you nee e 36 months prior to publicatior	ed by
Name of Entity		Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
Auris			rees•	Support• ✓		consultant. Consultant Fees and travel	
Ambu			✓			consultant. consultant Fees	Ī
Body Vision			✓	✓	✓	consultant. Consultant fees, travel, and i hold stock options	
Eolo			√	✓	✓	consultant. Consultant fees, travel, and i hold stock options	
Eon					✓	consultant. stock option holder	
Gravitas					✓	independent stock holder/investor	



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
Noah Medical		✓	✓		consultant. Consultant fees, travel, and i hold stock options
LX-Medical		✓			consultant. Consultant fees and i hold stock options
Med-Opsys				✓	partial owner of the company
Monogram Orthopedics				✓	independent stock holder/investor
Preora		✓		1./	consultant. Consultant fees and i hold stock options
/IDA				✓	consultant: stock option holder
Boston Scientific		✓	✓		consultant/speaker. fees for lectures and travel
lohnson and Johnson		✓			consultant
oncocyte		✓			consultant
veracyte		✓			consultant/speaker. fees for lectures and travel
Broncus		✓			consultant/speaker. fees for lectures
Gala		✓	✓		consultant. fees and travel
Heritage Biologics		✓			consultant
DbyDNA		\checkmark			consultant
Level-Ex		\checkmark			consultant
Medtronic		✓			consultant
Neurotronic		\checkmark			consultant
olympus		\checkmark			consultant
PulmonX		\checkmark	✓		consultant and travel
Astra-Zeneca		✓	✓		consultant/speaker. fees for lectures and travel
Biodesix		✓	✓		consultant/speaker. fees for lectures and travel
Genetech		✓	✓		consultant/speaker. fees for lectures and travel
Grifols		✓	✓		consultant/speaker. fees for lectures and travel
Takeda (formerl Shire, formerly Baxalta)		✓	✓		consultant/speaker. fees for lectures and travel
CSL		✓			consultant



nhibRX	□ □ □ DSMB				
Section 4.	Intellectual Property Patents & Copyrights				
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume No					
Section 5.	Relationships not covered above				
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?					
Yes, the following relationships/conditions/circumstances are present (explain below):					
✓ No other relationships/conditions/circumstances that present a potential conflict of interest					
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.					
Section 6.	Disclosure Statement				

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Hogarth reports personal fees and other from Auris, personal fees from Ambu, personal fees, non-financial support and other from Body Vision, personal fees and other from Eolo, other from Eon, other from Gravitas, personal fees and other from Noah Medical, personal fees and other from LX-Medical, other from Med-Opsys, other from Monogram Orthopedics, personal fees and other from Preora, other from VIDA, other from Viomics, personal fees from Boston Scientific, personal fees from Johnson and Johnson, personal fees from oncocyte, personal fees from veracyte, personal fees and other from Broncus, grants and personal fees from Gala, personal fees from Heritage Biologics, personal fees from IDbyDNA, personal fees from Level-Ex, personal fees from Medtronic, personal fees from Neurotronic, personal fees from olympus, personal fees from PulmonX, personal fees from Astra-Zeneca, personal fees from Biodesix, personal fees from Genetech, personal fees from Grifols, personal fees from Takeda, personal fees from CSL, personal fees from InhibRX, outside the submitted work; None of these COI have anything to do with this paper or my work on this paper.



Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.